Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft

David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board of directors, other execs join Merck, Apeiron Biologics, Vectura, Roivant, OncoSec, Breath Therapeutics, Immusoft and M3 Biotechnology.

Ex-Zealand Pharma AS head David Horn Solomon is joining Silence Therapeutics PLC as its new CEO, effective immediately. Previously, Solomon was the CEO of Bionor Pharma ASA and Akari Therapeutics PLC, and was the managing partner of Nordic healthcare fund, Sund Capital. He has earlier served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York City. Commenting on Silence’s prospects, Solomon said he was “particularly impressed” with the near-term opportunities, including the lead program in iron overload disorders which is progressing toward clinical trials.

Malin Corp. PLCc has appointed Ian Curley as chairman, effective immediately. Curley has had a long career in business and was most recently the CEO of Ardagh Group, which is listed on the NYSE. Malin also appointed healthcare executives Jean-Michel Cosséry and Rudy Mareel as non-executive directors

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Executives On The Move

More from Leadership